Pilot study to test Genomics England samples using Inivata’s InVisionTM platform

Inivata is collaborating with Genomics England to assess the quality of blood plasma samples and explore the potential of liquid biopsy to improve disease management and patient outcomes

In the first phase of a larger pilot, Inivata will analyse plasma samples donated by participants in Genomics England’s 100,000 Genomes Project. As well as determining the suitability of plasma, the study will focus on the use of Inivata’s world-leading liquid biopsy technology, InVision, to discover the mutations in the human genome that can lead to or demonstrate the presence of cancer.

These results, and those from the two subsequent phases, will be shared with researchers in the UK and around the world − with the potential to develop less invasive sample collection techniques, more effective monitoring processes and, ultimately, better cancer care.

Michael Stocum, Chief Executive Officer of Inivata, said, “As a company with a strong UK heritage, we are delighted to have partnered with the 100,000 Genomes Project - a world-leading initiative which is committed to keeping the UK at the forefront of medical innovation and care. This pilot study will enable us to combine our efforts through the sharing of insights and the assessment of how liquid biopsy technology could ultimately transform cancer care within the NHS, saving lives and money.”

Read more here.